Hims & Hers Health, Inc. (NYSE:HIMS) Receives $37.31 Average PT from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has earned a consensus recommendation of “Hold” from the fifteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $37.31.

HIMS has been the subject of a number of recent analyst reports. Bank of America boosted their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Piper Sandler upped their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Truist Financial upped their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $29.11 on Wednesday. Hims & Hers Health has a 1-year low of $11.20 and a 1-year high of $72.98. The company’s 50-day moving average is $39.88 and its 200 day moving average is $29.37. The firm has a market capitalization of $6.47 billion, a P/E ratio of 66.15 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Research analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the completion of the sale, the chief financial officer now directly owns 118,077 shares of the company’s stock, valued at approximately $2,885,801.88. This represents a 8.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,061,718 shares of company stock worth $37,894,395. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently bought and sold shares of HIMS. Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC raised its stake in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC raised its stake in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the period. Finally, State Street Corp grew its stake in Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.